• In late May 2026, CNBC’s Jim Cramer highlighted SELLAS Life Sciences Group on “Mad Money,” calling the biotech a “great spec” and giving it “two thumbs up,” while investors tracked progress in its Phase 3 REGAL trial for GPS in AML patients in remission but ineligible for stem cell transplant.
• Attention is also building around SELLAS’ second AML candidate, SLS009, with upcoming topline data viewed as a potentially important catalyst for the company’s development pipeline.
• With recent returns and growing focus on the Phase 3 REGAL trial, we will examine how this media spotlight shapes SELLAS’ investment narrative.

Find 46 companies with promising cash flow potential yet trading below their fair value.

What Is SELLAS Life Sciences Group's Investment Narrative?

To own SELLAS today, you really have to believe that its lead AML vaccine GPS and CDK9 inhibitor SLS009 can convert promising trial work into regulatory approvals and, eventually, commercial traction, despite the company having no revenue and ongoing losses. The market’s recent enthusiasm, capped by Jim Cramer’s “great spec” spotlight, seems to have amplified short term trading interest rather than changed the underlying story, where the Phase 3 REGAL readout and upcoming SLS009 topline data remain the core value drivers. Those milestones are still binary in nature, and the sharp share price run and premium price to book multiple could magnify downside if the data or funding picture disappoint. The recent media attention mostly increases expectations, not reduces the fundamental risks.

However, there is one funding-related risk that newer shareholders might be glossing over. Our comprehensive valuation report raises the possibility that SELLAS Life Sciences Group is priced higher than what may be justified by its financials.

Exploring Other Perspectives

Two Simply Wall St Community fair value views span US$1 to US$10 per share, underscoring how widely opinions differ. Set against binary REGAL and SLS009 outcomes and ongoing cash needs, that spread shows why it can pay to compare several viewpoints before forming a stance on SELLAS.

Explore 2 other fair value estimates on SELLAS Life Sciences Group - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your SELLAS Life Sciences Group research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free SELLAS Life Sciences Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SELLAS Life Sciences Group's overall financial health at a glance.

No Opportunity In SELLAS Life Sciences Group?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.